Recursion vs Superluminal Medicines
Which Drug Discovery AI tool is better in 2026?
Recursion
Pioneering AI-driven solutions in drug discovery to radically improve lives.
Superluminal Medicines
AI biotech company developing small-molecule drugs that target G protein-coupled receptors
Side-by-side
Recursion is the more established option (raised $500M); pricing is comparable on both sides.
| Metric | Recursion | Superluminal Medicines |
|---|---|---|
| Taglinei | Pioneering AI-driven solutions in drug discovery to radically improve lives. | AI biotech company developing small-molecule drugs that target G protein-coupled receptors |
| Foundedi | 2013🏆 | 2023 |
| HQi | Salt Lake City, US | — |
| Employeesi | 501-1000 | 11-50🏆 |
| Neuron scorei | 67🏆 | 51 |
| Total fundingi | $500M🏆 | $120M |
| Latest roundi | IPO · Apr 2021 | Series A |
| Valuationi | $2B🏆 | — |
| Cheapest paid plani | Pricing not disclosed | Pricing not disclosed |
| Free plani | ✗ | ✓ |
| Free triali | ✗ | ✓ |
| Top tier pricei | Pricing not disclosed | Pricing not disclosed |
| Pricing summaryi | Enterprise · Contact sales | Free |
| Categoriesi |
Capability matrix
Developer-facing capabilities and access signals for Recursion and Superluminal Medicines.
| Capability | Recursion | Superluminal Medicines |
|---|---|---|
| MCP support | ✗ | ✗ |
| Public API | ✗ | ✗ |
| Webhooks | ✗ | ✗ |
| OAuth 2.0 | ✗ | ✗ |
| SDK languages | — | — |
| Free plan | ✗ | ✓ |
| Free trial | ✗ | ✓ |
| Verified | ✗ | ✗ |
| Active deal | ✗ | ✗ |
🟢 Strengths of Recursion
- Has raised more capital ($500M vs $120M)
- Higher Neuron score (67 vs 51)
- More mature (2013)
🔵 Strengths of Superluminal Medicines
- Offers a free plan
- Offers a free trial
- Newer company (2023)
Which should you choose?
Choose Superluminal Medicines if price matters most — it starts at Free, which is friendlier for teams watching burn. Both Drug Discovery tools ship core features, so the cost delta often decides it for small teams and solo operators.
Choose Recursion if you want the most established option — it has raised $500M, suggesting more runway for enterprise features, support, and long-term roadmap. For mission-critical workflows or larger teams, that stability often outweighs a lower monthly price.
Frequently asked questions
Recursion vs Superluminal Medicines — which is better?
It depends on your priority. Recursion has raised more capital and is the more established option; Superluminal Medicines has broader feature depth. See the side-by-side table above.
Is Recursion cheaper than Superluminal Medicines?
No — Superluminal Medicines's cheapest paid plan is Free, while Recursion's is Enterprise · Contact sales.
Do Recursion and Superluminal Medicines offer free plans?
Recursion: Paid only. Superluminal Medicines: Yes, has a free plan.
Explore more Drug Discovery tools
Contextual paths to related AI startups, deals and rankings.